Abstract
Introduction

Amyotrophic lateral sclerosis (ALS) is a fatal disease characterized by motor neuron degeneration, leading to progressive paralysis and death from respiratory failure. Familial ALS (FALS) accounts for 5-10% of all patients and various genes are identified in FALS (1). Mutations of Cu/Zn superoxide dismutase gene (SOD1) are discovered as the first causative gene of FALS in 1993 (2). SOD1 mutations are linked with 20% of FALS patients. Over 100 kinds of SOD1 mutations are listed currently in FALS patients (http://alsod.iop.kcl.ac.uk/). Several kinds of SOD1 mutations are reported in Japanese ALS families. The clinicogenetic expression or new subtypes of FALS are addressed
. We encountered a Japanese family with a novel SOD1 mutation that has young onset and rapid proT a b l e 1 . S e r i a l Ch a n g e s o f B o d y Ma s s I n d e x , Re s p i r a t o r y F u n c t i o n a n d S e r u m Cr e a t i n i n e L e v e l s (7) . In a Japanese family with a missense mutation of serine to asparagine at codon 134 (S134N) of SOD1, a 65-year-old man, (8) .
Case Report
In a United Kingdom family with a mutation of histidine to glutamine at codon 48 (H48G) in exon 2, one patient had short survival and predominantly lower motor neurons signs (12) . Scandinavian FALS patients with SOD1 mutations also have heterogeneous clinico-genotypes, including rapidly progressive lower motor neuron disease (10) . Furthermore, the phenotype similar to the present family was described in FALS patients with a mutation of alanine to valine mutation at codon 4 (A4V) of SOD1; the proband had A4V mutation originated from the Farr family in Vermont, USA (13, 14) . This is the most common mutation in North America and accounts for 50% of SOD1-releated FALS (13) . Those patients suggest rapidly progressive form of pure lower motor neuron disease. The median survival (SD) from clinical onset is 1.0 (0.4) year (13) . Pathological examination also demonstrates severe involvement of lower motor neurons without upper motor neuron abnormalities in A4V-mutated patients (14) . Those 
